- Home
- TERN
as 05-13-2025 4:00pm EST
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 310.8M | IPO Year: | 2021 |
| Target Price: | $15.63 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.86 - $11.40 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Terns Pharmaceuticals Inc. (TERN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kuriakose Emil | TERN | Chief Medical Officer | Apr 1 '25 | Sell | $2.49 | 952 | $2,365.82 | 53,317 |
Latest Terns Pharmaceuticals Inc. News
TERN Breaking Stock News: Dive into TERN Ticker-Specific Updates for Smart Investing
Insider Monkey
5 days ago
Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?
GlobeNewswire
5 days ago
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
11 days ago
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
13 days ago
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Simply Wall St.
21 days ago
We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Zacks
a month ago
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Zacks
a month ago
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
GlobeNewswire
a month ago
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Compare TERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TERN Terns Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.